New hope for chinese patients with severe transplant complication: ruxolitinib trial launches

NCT ID NCT06462469

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug ruxolitinib in 36 Chinese adults and teens (12+) who have severe graft-versus-host disease after a stem cell transplant and did not improve with steroids. Participants take ruxolitinib pills daily for up to 56 days. The main goal is to see how many patients have a complete or partial response by day 28.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib (oral drug)
What this could lead to: If successful, this could provide a treatment option for Chinese patients with severe graft-versus-host disease that does not respond to steroids.
What could go wrong: This is a small, single-arm Phase 4 study with no placebo group, so results may be less reliable. The drug may not work for all patients and could have side effects like infections or blood cell changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450003, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430030, China
Novartis Investigative Site
RECRUITING

Changchun, Jilin, 130021, China
Novartis Investigative Site
RECRUITING

Xian, Shanxi, 710061, China
Novartis Investigative Site
RECRUITING

Chengdu, Sichuan, 610072, China
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site
RECRUITING

Beijing, 100028, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beijing, 100039, China
Novartis Investigative Site
RECRUITING

Beijing, 100070, China
Novartis Investigative Site
RECRUITING

Dalian, 116000, China
Novartis Investigative Site
RECRUITING

Fuzhou, 350001, China
Novartis Investigative Site
RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Taian, 271099, China
Novartis Investigative Site
RECRUITING

Tianjin, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.